Ara
Toplam kayıt 10, listelenen: 1-10
Physicians' Biological Drug Preference in Patients With Rheumatoid Arthritis and Spondyloarthritis With a History of Malignancy: Perspectives From the Treasure Database
(NLM (Medline), 2022)
OBJECTIVE: Because of concerns about malignancy risks, using biological disease-modifying antirheumatic drugs (bDMARDs) in patients with a history of malignancy remains a challenging issue in rheumatology practice. This ...
Are There Any Clues to Predict Bamboo Spine in Axial Spondyloarthritis?
(Wiley, 2020)
[No Abstract Available]
Short Term Efficacy of Tumor Necrosis Factor Inhibitors in Patients with non-radiographic Axial Spondylarthritis and ankylosing Spondylitis; Results from Turkbio Registry.
(Wiley-Blackwell, 2014)
[No Abstract Available]
Biological and targeted-synthetic disease-modifying antirheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: Real-life TReasure prospective data
(Clinical and Experimental Rheumatology S.A.S., 2021)
Objective To determine the real-life efficacy, safety, and drug-retention rates of leflunomide (LEF) or methotrexate (MTX) as a synthetic DMARD used in combination with biological DMARDs for rheumatoid arthritis (RA). ...
Leflunomide as a Concomitant DMARD Choice for the Biological Treatment Era of Rheumatoid Arthritis
(Wiley, 2018)
[No Abstract Available]
Uveitis-related Factors in Patients With Spondyloarthritis: TReasure Real-Life Results
(Elsevier Science Inc, 2021)
PURPOSE: Spondyloarthritis (SpA) is a group of diseases with overlapping skeletal and extra-articular features. Acute anterior uveitis (AAU) is the most common extra-articular manifestation of SpA. The relation between AAU ...
In the era of disease-modifying antirheumatic drugs, how close are we to treating rheumatoid arthritis without the use of glucocorticoids?
(Springer Heidelberg, 2021)
We wanted to see how close we could get to our goal of treating rheumatoid arthritis (RA) without the use of glucocorticoids (GCs) in the disease-modifying antirheumatic drugs (DMARDs) era using real-life data. Established ...
Disease characteristics of psoriatic arthritis patients may differ according to age at psoriasis onset: cross-sectional data from the Psoriatic Arthritis-International Database
(Clinical & Exper Rheumatology, 2021)
Objective To explore the impact of early versus late-onset psoriasis (PsO) on the disease characteristics of psoriatic arthritis (PsA) in a large-multicentre cohort. Methods The data from a multicentre psoriatic arthritis ...
Disease characteristics of psoriatic arthritis patients may differ according to age at psoriasis onset: Cross-sectional data from the psoriatic arthritis-international database
(Clinical and Experimental Rheumatology S.A.S., 2021)
Objective To explore the impact of early versus late-onset psoriasis (PsO) on the disease characteristics of psoriatic arthritis (PsA) in a large-multicentre cohort. Methods The data from a multicentre psoriatic arthritis ...